BR9609353A - Composição farmacêutica conveniente para administração em humanos processo para melhorar sintomas de uma desordem proliferativa celular e compostos - Google Patents

Composição farmacêutica conveniente para administração em humanos processo para melhorar sintomas de uma desordem proliferativa celular e compostos

Info

Publication number
BR9609353A
BR9609353A BR9609353A BR9609353A BR9609353A BR 9609353 A BR9609353 A BR 9609353A BR 9609353 A BR9609353 A BR 9609353A BR 9609353 A BR9609353 A BR 9609353A BR 9609353 A BR9609353 A BR 9609353A
Authority
BR
Brazil
Prior art keywords
humans
administration
compounds
pharmaceutical composition
composition suitable
Prior art date
Application number
BR9609353A
Other languages
English (en)
Portuguese (pt)
Inventor
Peng Cho Tang
Gerald Mcmahon
Davis G Harris
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Publication of BR9609353A publication Critical patent/BR9609353A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR9609353A 1995-06-07 1996-06-05 Composição farmacêutica conveniente para administração em humanos processo para melhorar sintomas de uma desordem proliferativa celular e compostos BR9609353A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47613695A 1995-06-07 1995-06-07
PCT/US1996/008741 WO1996040115A1 (en) 1995-06-07 1996-06-05 Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions

Publications (1)

Publication Number Publication Date
BR9609353A true BR9609353A (pt) 1999-05-11

Family

ID=23890650

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609353A BR9609353A (pt) 1995-06-07 1996-06-05 Composição farmacêutica conveniente para administração em humanos processo para melhorar sintomas de uma desordem proliferativa celular e compostos

Country Status (11)

Country Link
US (4) US5780496A (enExample)
EP (1) EP0831809A4 (enExample)
JP (1) JPH11506770A (enExample)
KR (1) KR19990022369A (enExample)
CN (1) CN1192680A (enExample)
AR (1) AR003140A1 (enExample)
BR (1) BR9609353A (enExample)
CA (1) CA2224103A1 (enExample)
IL (1) IL122427A0 (enExample)
MX (1) MX9709442A (enExample)
WO (1) WO1996040115A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593852A (en) * 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
CA2050057A1 (en) 1991-03-04 1992-09-05 Adam Heller Interferant eliminating biosensors
US5786488A (en) 1996-11-13 1998-07-28 Sugen, Inc. Synthetic methods for the preparation of indolyquinones
US6376529B1 (en) 1995-06-07 2002-04-23 Peng Cho Tang Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
EP0944720A1 (en) 1996-12-03 1999-09-29 Sugen, Inc. Adaptor protein frs2 and related products and methods
US6051597A (en) * 1997-06-13 2000-04-18 Merck & Co., Inc. Indolylquinones as antidiabetic agents
CA2321307A1 (en) 1998-02-27 1999-09-02 Venkatachala L. Narayanan Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
US6077849A (en) * 1998-04-02 2000-06-20 Merck & Co., Inc. Antidiabetic agents
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) * 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US20080076997A1 (en) * 1998-04-30 2008-03-27 Abbott Diabetes Care, Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) * 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6307090B1 (en) 1999-01-22 2001-10-23 The United States Of America As Represented By The Department Of Health And Human Services Acylated oligopeptide derivatives having cell signal inhibiting activity
WO2000056760A1 (en) * 1999-03-23 2000-09-28 The United States Of America, Represented By Secretary, Department Of Health And Human Services Phenylalanine derivatives
US7226991B1 (en) * 1999-03-23 2007-06-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylalanine derivatives
WO2001028577A2 (en) 1999-10-22 2001-04-26 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain
US7871981B2 (en) * 1999-10-22 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility, angiogenesis, and metastasis
US6165728A (en) * 1999-11-19 2000-12-26 Isis Pharmaceuticals Inc. Antisense modulation of NCK-2 expression
CA2419870A1 (en) * 2000-08-22 2002-02-28 Yang Gao Sh2 domain binding inhibitors
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US7151162B2 (en) * 2001-12-06 2006-12-19 The University Of Children's Hospital Of Both Cantons Of Basel Nuclear protein
US7057052B2 (en) 2002-09-26 2006-06-06 Duke University Heterocyclic quinones as pharmaceutical agents
EP1578262A4 (en) 2002-12-31 2007-12-05 Therasense Inc CONTINUOUS BLOOD SUGAR MONITORING SYSTEM AND USE METHOD
US20040138104A1 (en) * 2003-01-14 2004-07-15 The Government Of The United States Of America Represented By The Secretary, Peptides
US20050119163A1 (en) * 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
US8600920B2 (en) * 2003-11-28 2013-12-03 World Assets Consulting Ag, Llc Affinity propagation in adaptive network-based systems
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
JP2008532926A (ja) * 2004-12-06 2008-08-21 アバンテイス・フアルマ・エス・アー 置換インドール化合物、それを含有する組成物、この製造方法およびこの使用
FR2878849B1 (fr) * 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
NZ601635A (en) * 2010-01-27 2013-06-28 Takeda Pharmaceutical Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
US9912758B2 (en) 2014-12-16 2018-03-06 Yahoo Holdings, Inc. Continuing an application session on a different device
CN120365272A (zh) 2018-10-05 2025-07-25 安娜普尔纳生物股份有限公司 用于治疗与apj受体活性有关的疾病的化合物和组合物
KR102267662B1 (ko) * 2019-11-19 2021-06-22 한국화학연구원 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917820A (en) * 1969-05-29 1975-11-04 Canadian Patents Dev Antibiotic cochliodinol and production by chaetomium, cochliodes and chaetomium globsum
JPH0236591B2 (ja) * 1979-08-27 1990-08-17 Kyoto Pharma Ind Kinonjudotai
JPS6191167A (ja) * 1984-10-08 1986-05-09 Kyoto Yakuhin Kogyo Kk キノン誘導体
JPS6360966A (ja) * 1986-08-29 1988-03-17 Kyoto Yakuhin Kogyo Kk キノン誘導体
SE8903455D0 (sv) * 1989-10-19 1989-10-19 Joakim Nelson Dynamiska digitala foerbindelsenaet (dfn)
US5469431A (en) * 1993-07-12 1995-11-21 Philips Electronics North America Corp. Method of and apparatus for channel mapping with relative service identification
DE4329010A1 (de) * 1993-08-28 1995-03-02 Sel Alcatel Ag Funksystem
US6205143B1 (en) * 1996-03-14 2001-03-20 Telefonaktiebolaget L M Ericsson System supporting variable bandwidth asynchronous transfer mode network access for wireline and wireless communications
US5841777A (en) * 1996-08-30 1998-11-24 Hewlett-Packard Company System and method for accommodating ABR and CBR traffic on a shared communications channel
US6363058B1 (en) * 1997-09-24 2002-03-26 Telefonaktiebolaget L M Ericsson (Publ) Multi-service handling by a single mobile station
FI980293A7 (fi) * 1998-02-09 1999-08-10 Nokia Corp Multimedia- ja monipalvelupuhelut matkaviestinverkossa
CN1284243A (zh) * 1998-11-30 2001-02-14 诺基亚网络有限公司 空中接口容量调度方法

Also Published As

Publication number Publication date
IL122427A0 (en) 1998-06-15
WO1996040115A1 (en) 1996-12-19
CA2224103A1 (en) 1996-12-19
AR003140A1 (es) 1998-07-08
US20020016353A1 (en) 2002-02-07
US6239161B1 (en) 2001-05-29
JPH11506770A (ja) 1999-06-15
CN1192680A (zh) 1998-09-09
EP0831809A1 (en) 1998-04-01
MX9709442A (es) 1998-02-28
KR19990022369A (ko) 1999-03-25
AU5979996A (en) 1996-12-30
EP0831809A4 (en) 2001-11-28
US5780496A (en) 1998-07-14
AU697120B2 (en) 1998-09-24
US6090838A (en) 2000-07-18

Similar Documents

Publication Publication Date Title
BR9609353A (pt) Composição farmacêutica conveniente para administração em humanos processo para melhorar sintomas de uma desordem proliferativa celular e compostos
BR9709267A (pt) Preparação de anticorpo monoclonal para administração a um humano formulação farmacêutica uso de uma preparação de anticorpo monoclonal e processo para a fabricação de uma preparação de anticorpo monoclonal
BR9508586A (pt) Compostos processo de preparação dos mesmos uso dos mesmos processo de tratamento de uma condição clínica em um mamífero e composição farmacêutica
BR9611410A (pt) Método e composição farmacêutica para regular a concentração de lipídios
BR9505815A (pt) Composto processos para a preparação do mesmo e para obter um efeito anti-isquêmico e anti-hipertensivo e para produzir atividade agonista 2 pré-sináptica e antagonista 1 pós-sináptica em um paciente e composição farmacêutica
EE9900296A (et) Suure bioomastatavusega fenofibraatide ravimkoostis ja meetod selle valmistamiseks
BR9510302A (pt) Forma de dosagem farmacêutical de liberação controlada método para tratamento sintomático da tosse método para preparar uma forma de dosagem farmacêutica de liberação controlada composição para uso no tratamento sintomático da tosse e aplicação de uma forma dosagem de moguisteina de liberação controlada
BR9406566A (pt) Composição farmacêutica uso de progesterona e/ou 17 - - estradiol e processo para a fabricação de uma preparação farmacêutica
BR9705926A (pt) Composição tópica utilização e processo para limitar diminuir e/ou impedir a transfêrencia de uma composição
EE03399B1 (et) Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess
BR9604950A (pt) Composição farmacêutica contendo n-clorofenil carbamatos n-clorofeniltiocarbamatos e derivados de n-fosfonoglicina para inibir o crescimento de cânceres e vírus em mamíferos
BR9610988A (pt) Composto uso do mesmo fomulação farmacêutica e processo para produção do composto
DK0833612T3 (da) Ny farmaceutisk sammensætning med bedøvende virkning
ATE262907T1 (de) Pharmazeutische zubereitung zur topischen applikation enthaltend acyclovir und hydrokortison
BR9404114A (pt) Composição farmacêutica e seu processo de preparação
BR9504509A (pt) Composto processo para sua preparaçao e formulaçao farmaceûtica
BR9609330A (pt) Derivado de difenilmetileno piperidina composição farmacêutica e processo para preparação e uso do derivado de difenilmetileno piperidina
BR9206950A (pt) Composição farmacêutica e processo para sua preparação
NO20016068L (no) Anvendelse av oksypurin-nukleosider for fremstilling av et farmasöytisk preparat for redusering av inflammasjon i et dyr
BR9401965A (pt) Composição farmecêutica antialérgica para administração tópica oftálmica e processo para produzir a mesma
BR9701085A (pt) Derivado de vitamina d cristalina processo para preparar o mesmo medicamento composição farmacéutica processo para preparar a mesma e uso do derivado
EE9900114A (et) 1,2,3,4-tetrahüdrobensofuro[3,4-c]püridiini derivaadid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
DE69415570D1 (de) Esculetin Derivate und pharmazeutische Zusammenstellung
FI972949L (fi) Lääkemuoto kollagenaasin vapauttamiseksi haavoihin ja sen valmistusmenetelmiä
BR9608407A (pt) Uso de um composto preparação farmacéutica para uso na profilaxa e/ou tratamento de insuficiência de orgãos múltiplos sistemas e processo para profilaxia e tratamento de insuficiência de órgãos de múltiplos sistemas em mamíferos incluindo homem

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law